6-MP Tablets
Molecule: Mercaptopurine
Strength: 50 mg
Quantity: 100 Tablets
Form: Tablet
Packaging Type: Strip
Manufacturer/Marketed By: Zydus
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
No similar products found.
Description
6-MP 50mg Tablet (Mercaptopurine) is an anti-cancer medicine used in the treatment of acute lymphoblastic leukemia (ALL). It slows abnormal cell growth and supports long-term remission. Use only under medical supervision.
Benefits
-
Helps reduce abnormal white blood cell growth
-
Supports long-term remission in ALL patients
-
Enhances treatment outcomes in combination therapy
-
Oral tablet makes it convenient to take
Indications and Usage
-
Treatment of Acute Lymphoblastic Leukemia (ALL)
-
Used as maintenance therapy to help prevent relapse
-
May be prescribed for certain autoimmune or inflammatory disorders by specialists
This medicine must be used under strict medical supervision with routine blood tests.
How it Works
Mercaptopurine blocks DNA and RNA synthesis in rapidly dividing cells, slowing the multiplication of cancerous blood cells. This helps control disease progression and maintain remission.
Dosage & Administration
-
Usually taken once daily or as directed by the oncologist
-
Dosage is adjusted based on weight, treatment phase, and blood test results
-
Take at the same time each day
-
Do not skip or double doses
-
Regular blood monitoring is essential
Side Effects
Common side effects include:
-
Nausea, vomiting
-
Loss of appetite
-
Fatigue or weakness
-
Low blood counts (anemia, neutropenia)
-
Liver enzyme elevation
Seek urgent medical help if you notice jaundice, unusual bleeding, fever, or signs of infection.
Warning and Precaution
-
Avoid use during pregnancy and breastfeeding unless approved by a doctor
-
Regular blood count and liver function monitoring required
-
Avoid live vaccines
-
Inform your doctor if you have liver disorders or TPMT enzyme deficiency
-
Avoid alcohol and excessive sun exposure
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »April 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.